86. 肺動脈性肺高血圧症 [臨床試験数:1,083,薬物数:667(DrugBank:122),標的遺伝子数:98,標的パスウェイ数:185

Searched query = "Pulmonary arterial hypertension", "PAH", "IPAH", "HPAH", "Eisenmenger syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00866983
(ClinicalTrials.gov)
October 200920/3/2009Local Open-Label Access Study For Patients Who Completed A1481244 Study In BrazilA Local, Multi-Centre, Extension, Open Label Access Study, To Provide Sildenafil Therapy For Patients Who Completed A1481244 Study And Are Judged By The Investigator To Derive Clinical Benefit From Continued Treatment With Sildenafil , Prior To Reimbursement And Availability For Patients In Brazil.Pulmonary Arterial HypertensionDrug: sildenafil (Revatio) 20 mg TIDPfizerNULLNo longer available18 YearsN/ABothPhase 4Brazil
2EUCTR2006-004705-26-GB
(EUCTR)
10/05/200717/04/2007Safety and Tolerability of Sildenafil in Patients with Eisenmenger PhysiologySafety and Tolerability of Sildenafil in Patients with Eisenmenger Physiology Eisenmenger Syndrome (pulmonary hypertension due to congenital heart disease)
MedDRA version: 8.1;Level: LLT;Classification code 10058554;Term: Eisenmenger's syndrome
Trade Name: Revatio ® 20 mg film-coated tablets
Product Name: Sildenafil
INN or Proposed INN: Sildenafil (REVATIO)
Imperial College LondonNULLNot RecruitingFemale: yes
Male: yes
12Phase 4United Kingdom